Please take this 2-3 minute survey, meant to gather insights on the first-line targeted treatments of EGFR mutation-positive NSCLC. Lung cancer is one of the most common cancers. GLOBOCAN 2020 data shows, in India over 5% of new cancer cases are lung cancers, constituting about 7.8% of all cancer deaths. 1 As per published data Indian prevalence of EGFR mutations in adenocarcinoma NSCLC patients was around 36.9%. Females and non-smokers are more likely to harbor an EGFR mutation.
2,3 Treatment strategies for patients with advanced‑stage NSCLC have markedly changed, from the empirical use of cytotoxic agents to targeted regimens. EGFR tyrosine kinase inhibitors (TKIs), the first‑line therapy for advanced NSCLC, are reported to be the most effective. 4 References: The Global Cancer Observatory. [Internet] [March, 2021]. Available at:…
